Cognition Therapeutics, Inc.

Congrats to our research team and their co-authors, who recently published an analysis of proteomics from the first cohort of the Phase 2 COG0201 ‘SHINE’ study in the journal Neurobiology of Disease: https://bityl.co/R1yH. The analysis supports our understanding of CT1812’s impact on pathways related to amyloid biology, synapse and neuroinflammation, hallmarks of #Alzheimers disease pathology #biomarkers #dementia #biotech

Congratulations, Dr. Rissman. A well-deserved acknowledgement of your accomplishments. #alzheimers #dementia

In case you missed it, last week we announced that four abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 'SHINE' study of CT1812 have been accepted for poster presentation at AAIC coming up in Philadelphia. #AAIC2024 #alzheimers #clinicaltrials Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC Read more here: https://lnkd.in/ePS4b3qi

See this morning's press release here https://lnkd.in/ePS4b3qi

See you in Philadelphia! Four abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 'SHINE' study of CT1812 have been accepted for poster presentation at the upcoming #AAIC2024. #alzheimers #clinicaltrials #dementia

A few days back from the #LongwoodHealthcareLeaders Spring MIT event in Cambridge. What a pleasure to interact with industry leaders, academics, government officials, and colleagues former and new. The Longwood Healthcare Leaders team outdid themselves yet again, assembling thought leaders who weighed in on the key issues of our industry, to the benefit of all who attended. My thanks to my fellow panelists – AbCellera CEO, Carl Hansen; Aurion Biotech CSO, Arnaud Lacoste, PhD MBA; Voyager Therapeutics CEO, Al Sandrock; Carbon Biosciences President and CEO, Joel Schneider; and MIT McGovern Institute Fellow, Omar Abudayyeh - who joined me in a discussion of #NextGenTherapeutics. 

Celebrating today #TheLongestDay! Learn more about efforts to #ENDALZ here. A great day to get involved and get inspired! Learn more from Alzheimer's Association® here #AlzheimersDisease https://lnkd.in/dJ9uGAwj

“Nobody believes . . . that there’s a single target,” CEO Lisa Ricciardi, speaking with BioSpace's Kate Goodwin on the potential for combo treatments in #AlzheimersDisease. See the full article here. https://lnkd.in/eKc-ZCEt

Learn about how Susan Catalano, co-founder of the #NIAFunded Cognition Therapeutics, Inc., utilized SBIR/STTR grants to further the development of a drug to target the main toxin linked to Alzheimer's: https://go.nih.gov/OOMELXA #AlzheimersDisease #HealthEquity #DiversifySBIR

The recommendation from the Peripheral and Central Nervous System Drugs Advisory Committee in favor of approving donanemab mark’s another important step for the Alzheimer’s disease community. We are encouraged by the entry of an additional therapy that brings more options to patients and their families. Today, the committee thoughtfully considered important questions surrounding the safety and efficacy profile of this molecule, and unique aspects of the clinical trials undertaken such as diagnostic entry criteria, appropriate clinical endpoints and duration of treatment.    The positive outlook for donanemab signals an important advance in the understanding of Alzheimer’s disease that validates the mechanism of action for CT1812 and its ability to act as a neuroprotective agent. We congratulate Eli Lilly for their relentless commitment to bringing new Alzheimer’s treatment to the fight.